Galapagos NV (NASDAQ:GLPG - Get Free Report)'s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $28.79, but opened at $29.49. Galapagos shares last traded at $29.40, with a volume of 130,033 shares.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the company. Kepler Capital Markets lowered Galapagos from a "hold" rating to a "reduce" rating in a research note on Wednesday, November 20th. Royal Bank of Canada decreased their price target on Galapagos from $32.00 to $30.00 and set a "sector perform" rating on the stock in a research note on Friday, November 1st. Two investment analysts have rated the stock with a sell rating and six have assigned a hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $30.75.
Get Our Latest Report on GLPG
Galapagos Stock Down 2.2 %
The firm has a fifty day moving average price of $27.23 and a 200 day moving average price of $27.49.
Hedge Funds Weigh In On Galapagos
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Creative Planning acquired a new stake in shares of Galapagos in the second quarter valued at approximately $456,000. Crossmark Global Holdings Inc. bought a new position in Galapagos in the 3rd quarter valued at $1,077,000. Signaturefd LLC increased its stake in shares of Galapagos by 65.6% in the 3rd quarter. Signaturefd LLC now owns 6,413 shares of the biotechnology company's stock valued at $185,000 after buying an additional 2,541 shares during the period. Headlands Technologies LLC raised its position in shares of Galapagos by 56.7% during the second quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 446 shares during the last quarter. Finally, Stonepine Capital Management LLC lifted its stake in shares of Galapagos by 23.2% during the second quarter. Stonepine Capital Management LLC now owns 485,000 shares of the biotechnology company's stock valued at $12,018,000 after acquiring an additional 91,366 shares during the period. Institutional investors and hedge funds own 32.46% of the company's stock.
About Galapagos
(
Get Free Report)
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Featured Stories
Before you consider Galapagos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.
While Galapagos currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
